Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Cappelli

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
RMD Open|September 12, 2022
Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Clifton O Bingham, Patrick M Forde, et al.
Seminars in Arthritis and Rheumatism|March 26, 2018
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimenLaura C Cappelli, Julie R Brahmer, Patrick M Forde, et al.
Frontiers in Immunology|December 6, 2018
Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid ArthritisErika Darrah, Jon T Giles, Ryan L Davis, et al.
Seminars in Arthritis and Rheumatism|May 11, 2024
Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosisRachel S Wallwork, Jonathan J Kotzin, Laura C Cappelli, et al.
Arthritis Research & Therapy|April 1, 2025
Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritisElise F Gray-Gaillard, Ami A Shah, Clifton O Bingham Iii, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
Annals of the Rheumatic Diseases|September 22, 2019
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessationTawnie J Braaten, Julie R Brahmer, Patrick M Forde, et al.
Arthritis Care & Research|April 14, 2019
Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessment Measures in Rheumatoid ArthritisStephanie C Kulhawy-Wibe, JoAnn Zell, Kaleb Michaud, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabLaura C Cappelli, Anna Kristina Gutierrez, Alan N Baer, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
RMD Open|September 12, 2022
Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritisLaura C Cappelli, Clifton O Bingham, Patrick M Forde, et al.
Seminars in Arthritis and Rheumatism|March 26, 2018
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimenLaura C Cappelli, Julie R Brahmer, Patrick M Forde, et al.
Frontiers in Immunology|December 6, 2018
Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid ArthritisErika Darrah, Jon T Giles, Ryan L Davis, et al.
Seminars in Arthritis and Rheumatism|May 11, 2024
Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosisRachel S Wallwork, Jonathan J Kotzin, Laura C Cappelli, et al.
Arthritis Research & Therapy|April 1, 2025
Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritisElise F Gray-Gaillard, Ami A Shah, Clifton O Bingham Iii, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
Annals of the Rheumatic Diseases|September 22, 2019
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessationTawnie J Braaten, Julie R Brahmer, Patrick M Forde, et al.
Arthritis Care & Research|April 14, 2019
Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessment Measures in Rheumatoid ArthritisStephanie C Kulhawy-Wibe, JoAnn Zell, Kaleb Michaud, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabLaura C Cappelli, Anna Kristina Gutierrez, Alan N Baer, et al.
Pageof 6